|
1) 持田 智, 中山伸朗, 名越澄子, 他. ①劇症肝炎の診断基準: プロトロンビン時間の扱いに関する検討, ②劇症肝炎, 急性肝不全の概念の改変, ③肝移植適応ガイドラインの改訂. 厚生労働科学研究費補助金(難治性疾患克服研究事業) ｢難治性の肝・胆道疾患に関する調査研究｣ 平成21年度研究報告書. 2010. p.89-92
|
|
|
|
|
2) 坪内博仁, 桶谷 真, 井戸章雄, 他. 劇症肝炎及び遅発性肝不全(LOHF: late onset hepatic failure)の全国集計(2008年). 厚生労働科学研究費補助金難治性疾患克服研究事業 ｢難治性の肝・胆道疾患に関する調査研究｣ 平成21年度研究報告書. 2010. p.95-106
|
|
|
|
|
|
3) Lammert C, Einarsson S, Saha C, et al. Relationship between daily dose of oral medications and idiosyncratic drug-induced liver injury: search for signals. Hepatology. 2008; 47: 2003-9
|
|
|
|
|
4) Lammert C, Bjornsson E, Niklasson A, et al. Oral medications with significant hepatic metabolism at higher risk for hepatic adverse events. Hepatology. 2010; 51: 615-20
|
|
|
|
|
|
5) Jacob S, Khan A, Jacobs ER, et al. Prolonged hypothermia as a bridge to recovery for cerebral edema and intracranial hypertension associated with fulminant hepatic failure. Neurocrit Care. 2009; 11: 242-6
|
|
|
|
|
|
6) Yokoi T, Oda S, Shiga H, et al. Efficacy of high-flow dialysate continuous hemodiafiltration in the treatment of fulminant hepatic failure. Transfus Apher Sci. 2009; 40: 61-70
|
|
|
|
|
|
7) Inoue K, Kourin A, Watanabe T, et al. Artificial liver support system using large buffer volumes removes significant glutamine and is an ideal bridge to liver transplantation. Transplant Proc. 2009; 41: 259-61
|
|
|
|
|
|
8) Arata S, Tanaka K, Takayama K, et al. Treatment of hepatic encephalopathy by on-line hemodiafiltration: a case series study. BMC Emerg Med. 2010; 10: 10
|
|
|
|
|
|
9) Degertekin B, Lok AS. Indications for therapy in hepatitis B. Hepatology. 2009; 49(5 Suppl): S129-37
|
|
|
|
|
|
10) 藤原研司, 持田 智, 松井 淳. 劇症肝炎及び遅発性肝不全(LOHF: late onset hepatic failure)の全国集計(2003年). 厚生労働科学研究費補助金難治性疾患克服研究事業 ｢難治性の肝疾患に関する調査研究｣ 平成16年度研究報告書. 2005. p.93-107
|
|
|
|
|
|
11) Yu JW, Sun LJ, Zhao YH, et al. The study of efficacy of lamivudine in patients with severe acute hepatitis B. Dig Dis Sci. 2010; 55: 775-83
|
|
|
|
|
|
12) Miyake Y, Iwasaki Y, Takaki A, et al. Lamivudine treatment improves the prognosis of fulminant hepatitis B. Intern Med. 2008; 47: 1293-9
|
|
|
|
|
13) Jochum C, Gieseler RK, Gawlista I, et al. Hepatitis B-associated acute liver failure: immediate treatment with entecavir inhibits hepatitis B virus replication and potentially its sequelae. Digestion. 2009; 80: 235-40
|
|
|
|
|
|
14) 坪内博仁, 熊田博光, 清澤研道, 他. 免疫抑制・化学療法により発症するB型肝炎対策-厚生労働省｢難治性の肝・胆道疾患に関する調査研究｣班劇症肝炎分科会および｢肝硬変を含めたウイルス性肝疾患の治療の標準化に関する研究｣班合同報告-. 肝臓. 2009; 50: 38-42
|
|
|
|
|
|
15) Kotoh K, Enjoji M, Nakamuta M, et al. Arterial steroid injection therapy can inhibit the progression of severe acute hepatic failure toward fulminant liver failure. World J Gastroenterol. 2006; 12: 6678-82
|
|
|
|
|
|
16) Inoue K, Sekiyama K, Yamada M, et al. J Combined interferon alpha2b and cyclosporin A in the treatment of chronic hepatitis C: controlled trial. Gastroenterol. 2003; 38: 567-72
|
|
|
|
|
|
17) Nakagawa M, Sakamoto N, Tanabe Y, et al. Suppression of hepatitis C virus replication by cyclosporin A is mediated by blockade of cyclophilins. Gastroenterology. 2005; 129: 1031-41
|
|
|
|
|
|
18) 日本肝移植研究会: 肝移植症例登録(第二報). 移植. 2008; 43: 45-55
|
|
|
|
|
|
19) Mochida S, Nakayama N, Matsui A, et al. Re-evaluation of the Guideline published by the Acute Liver Failure Study Group of Japan in 1996 to determine the indications of liver transplantation in patients with fulminant hepatitis. Hepatol Res. 2008; 38: 970-9
|
|
|
|
|
|
20) 持田 智, 中山伸朗, 名越澄子, 他. 急性肝不全の予後予測: データマイニングによるアルゴリズムの作成 厚生労働科学研究費補助金(難治性疾患克服研究事業) ｢難治性の肝・胆道疾患に関する調査研究｣ 平成21年度研究報告書. 2010. p.111-3
|
|
|
|
|
|
21) 持田 智, 中山伸朗, 森吉美穂, 他. ①劇症肝炎の診断基準: プロトロンビン時間の扱いに関する検討, ②劇症肝炎, 急性肝不全の概念の改変, ③肝移植適応ガイドラインの改訂. 厚生労働科学研究費補助金(難治性疾患克服研究事業) ｢難治性の肝・胆道疾患に関する調査研究｣ 平成19年度研究報告書. 2008. p.110-3
|
|
|
|
|
|
22) Millis J, Losanoff J. Technology insight: liver support systems. Nat Clin Pract Gastroenterol Hepatol. 2005; 2: 398-405
|
|
|
|
|
|
23) Demetriou A, Brown R, Busuttil R, et al. Prospective, randomized, multicenter, controlled trial of a bioartificial liver in treating acute liver failure. Ann Surg. 2004; 239: 660-70
|
|
|
|
|
|
24) Nyberg S, Hardin J, Amiot B, et al. Rapid, large-scale formation of porcine hepatocyte spheroids in a novel spheroid reservoir bioartificial liver. Liver Transpl. 2005; 11: 901-10. Artif Organs. 2007; 31: 148-51
|
|
|
|
|
|
25) Kanai H, Marushima H, Kimura N, et al. Extracorporeal bioartificial liver using the radial-flow bioreactor in treatment of fatal experimental hepatic encephalopathy. Artif Organs. 2007; 31: 148-51
|
|
|
|
|
|
26) Ido A, Tsubouchi H. Translational research to identify clinical applications of hepatocyte growth factor. Hepatol Res. 2009; 39: 739-47
|
|
|
|
|
|
27) Terai S, Sakaida I. Current status of autologous bone marrow cell infusion therapy for liver cirrhosis patients. Hepatol Res. 2008; 38(suppl): S72-5
|
|
|
|
|
|
28) Stutchfield BM, Forbes SJ, Wigmore SJ. Prospects for stem cell transplantation in the treatment of hepatic disease. Liver Transpl. 2010; 16: 827-36
|
|
|
|
|
|
29) Si-Tayeb K, Noto FK, Nagaoka M, et al. Highly efficient generation of human hepatocyte-like cells from induced pluripotent stem cells. Hepatology. 2010; 51: 297-305
|
|
|
|
|